Skip to main content

Advertisement

Table 2 Treatment strategies at baseline and last follow-up

From: Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters

Treatment strategies, n (%) of patients with At baseline evaluation At last persistence evaluation
Oral corticosteroids 42 (36.5) 48 (41.7)
Methotrexate monotherapy 20 (17.4) 43 (37.4)
2 combined DMARDs (methotrexate required) 68 (59.1) 40 (34.8)
≥3 combined DMARDs (methotrexate required) 21 (18.3) 22 (19.1)
Other combinations of traditional DMARDs 6 (5.2) 10 (8.7)
Biologic DMARDs 0 5 (4.3)
  1. DMARDs disease-modifying anti-rheumatic drugs